AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26617438 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of XAT and morphine (20 mg and 30 mg, respectively)
Number of subjects: 0
Study 26617438 — intervention group
Group type: EXPERIMENTAL
Intervention: XAT treatment
Number of subjects: 0
Study 25096178 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 10
Study 25096178 — intervention group
Group type: COMPARATOR
Intervention: MOD
Number of subjects: 10
Study 22531635 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen or letrozole or a sequence of the two (5 years)
Number of subjects: 100
Study 19193708 — intervention group
Group type: EXPERIMENTAL
Intervention: Silanated RC surfaces
Number of subjects: 60
Study 19193708 — intervention group
Group type: COMPARATOR
Intervention: Non-silanated RC surfaces
Number of subjects: 60
Study 18214123 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg daily for eight weeks
Number of subjects: 60
Study 18214123 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg daily for eight weeks
Number of subjects: 60
Study 18214123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15259325 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of standard training for spatial scanning and optokinetic stimulation
Number of subjects: 2
Study 15259325 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for spatial scanning
Number of subjects: 2
Study 10929897 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office test detecting IgG antibodies to H. pylori (FlexPack HP, Abbott Diagnostics)
Number of subjects: 183
Study 10929897 — intervention group
Group type: COMPARATOR
Intervention: IgG serum antibodies
Number of subjects: 183
Study 10929897 — intervention group
Group type: COMPARATOR
Intervention: IgA antibodies
Number of subjects: 183
Study 10929897 — intervention group
Group type: COMPARATOR
Intervention: Whole-blood test
Number of subjects: 183
Study 9306027 — intervention group
Group type: EXPERIMENTAL
Intervention: Durex Ramses lubricated condoms
Number of subjects: 4637
Study 7687079 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilatation of the prostate (BDP)
Number of subjects: 51
Study 7687079 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 51
Study 3470899 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hexetidine and zinc ions
Number of subjects: 10
Study 3470899 — intervention group
Group type: COMPARATOR
Intervention: Hexetidine
Number of subjects: 10
Study 3470899 — intervention group
Group type: COMPARATOR
Intervention: Zinc ions
Number of subjects: 10
Study 31355924 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone call
Number of subjects: 620
Study 31355924 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal call
Number of subjects: 620
Study 31355924 — intervention group
Group type: COMPARATOR
Intervention: No follow-up call
Number of subjects: 620
Study 27405512 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) program offered yearly from age 2 to 10.
Number of subjects: 731
Study 27405512 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) program
Number of subjects: 731
Study 26932169 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT plus vitamin D supplementation (1000 IU daily)
Number of subjects: 50
Study 26932169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26932169 — intervention group
Group type: COMPARATOR
Intervention: SLIT plus placebo
Number of subjects: 50
Study 24586591 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient chart review training
Number of subjects: 123
Study 24586591 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 123
Study 22868933 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive behavioral intervention for tics
Number of subjects: 122
Study 22868933 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment
Number of subjects: 122
Study 20969659 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% polyacrylamide hydrogel
Number of subjects: 315
Study 20969659 — intervention group
Group type: COMPARATOR
Intervention: nonanimal stabilized hyaluronic acid (NASHA)
Number of subjects: 315
Study 17653846 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined urinary and recombinant FSH (uFSH followed by rFSH)
Number of subjects: 119
Study 17653846 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH)
Number of subjects: 119
Study 15682300 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 26
Study 15682300 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg)
Number of subjects: 26
Study 15682300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12237477 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 0
Study 12237477 — intervention group
Group type: COMPARATOR
Intervention: 3 episodes of 1 min ischemia
Number of subjects: 0
Study 10424181 — intervention group
Group type: EXPERIMENTAL
Intervention: One-person transferring techniques
Number of subjects: 17
Study 10424181 — intervention group
Group type: EXPERIMENTAL
Intervention: Single hook method for repositioning
Number of subjects: 17
Study 10424181 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-person draw sheet repositioning technique
Number of subjects: 17
Study 10424181 — intervention group
Group type: EXPERIMENTAL
Intervention: General patient handling tasks
Number of subjects: 17
Study 7493303 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 321
Study 1968912 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol LA (160 mg)
Number of subjects: 12
Study 1968912 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol CR/ZOK (100 mg)
Number of subjects: 12
Study 1968912 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 12
Study 1968912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 437431 — intervention group
Group type: EXPERIMENTAL
Intervention: β-sitosterol (250 mg/kg/day)
Number of subjects: 7
Study 437431 — intervention group
Group type: EXPERIMENTAL
Intervention: chenic acid (10 mg/kg/day)
Number of subjects: 7
Study 437431 — intervention group
Group type: EXPERIMENTAL
Intervention: β-sitosterol + chenic acid
Number of subjects: 7
Study 30517043 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective tibialis posterior strengthening and iliopsoas stretching
Number of subjects: 28
Study 30517043 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise (towel curl exercises only)
Number of subjects: 28
Study 27883237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside (1200 mg)
Number of subjects: 65
Study 27883237 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (mean daily dose of 70.5 mg)
Number of subjects: 65
Study 25572026 — intervention group
Group type: EXPERIMENTAL
Intervention: TiNO stents
Number of subjects: 302
Study 25572026 — intervention group
Group type: COMPARATOR
Intervention: E-ZES
Number of subjects: 302
Study 23493575 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 22
Study 23493575 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 22
Study 21437754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical feedback device
Number of subjects: 81
Study 21437754 — intervention group
Group type: COMPARATOR
Intervention: Classic ECC without the device
Number of subjects: 81
Study 19679266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 19679266 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study 17374038 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone + Cognitive Behavioral Therapy (CBT)
Number of subjects: 137
Study 17374038 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone + Motivational Enhancement Therapy (MET)
Number of subjects: 137
Study 17374038 — intervention group
Group type: COMPARATOR
Intervention: Placebo + CBT
Number of subjects: 137
Study 17374038 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MET
Number of subjects: 137
Study 15353385 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day (12 mg bid)
Number of subjects: 699
Study 11517441 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine and didanosine (group 1)
Number of subjects: 42
Study 11517441 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and lamivudine (group 2)
Number of subjects: 42
Study 9664749 — intervention group
Group type: EXPERIMENTAL
Intervention: Avitriptan 75 mg
Number of subjects: 48
Study 9664749 — intervention group
Group type: EXPERIMENTAL
Intervention: Avitriptan 150 mg
Number of subjects: 48
Study 9664749 — intervention group
Group type: EXPERIMENTAL
Intervention: Avitriptan 200 mg
Number of subjects: 48
Study 9664749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8143828 — intervention group
Group type: EXPERIMENTAL
Intervention: ECSC prediction equations for spirometric indices
Number of subjects: 100
Study 30368884 — intervention group
Group type: EXPERIMENTAL
Intervention: EMT regulators expression in WI-FTC, PDTC, and ATC
Number of subjects: 62
Study 30368884 — intervention group
Group type: COMPARATOR
Intervention: EMT regulators expression in FA and MI-FTC
Number of subjects: 62
Study 30368884 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of E-CAD and EMT regulators expression
Number of subjects: 62
Study 30368884 — intervention group
Group type: EXPERIMENTAL
Intervention: EMT regulators expression
Number of subjects: 62
Study 30124488 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient blood management program
Number of subjects: 1000
Study 26272237 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Radical Cystectomy (ORC)
Number of subjects: 93
Study 26272237 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Radical Cystectomy (RARC)
Number of subjects: 93
Study 26272237 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Radical Cystectomy (LRC)
Number of subjects: 93
Study 24493829 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 95
Study 24493829 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 95
Study 24493829 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL2L11 high expression
Number of subjects: 95
Study 22760584 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency tone presented in synchrony with the target display among low-tone distractors
Number of subjects: 0
Study 22760584 — intervention group
Group type: EXPERIMENTAL
Intervention: Louder tone presented amongst quieter tones
Number of subjects: 0
Study 22760584 — intervention group
Group type: EXPERIMENTAL
Intervention: Quieter tone presented amongst louder tones
Number of subjects: 0
Study 22760584 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of a tone in an otherwise identical tone sequence
Number of subjects: 0
Study 20546262 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS)
Number of subjects: 442
Study 20546262 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir
Number of subjects: 442
Study 17397703 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagine-patient perspective-taking
Number of subjects: 0
Study 17397703 — intervention group
Group type: COMPARATOR
Intervention: Neutral perspective-taking
Number of subjects: 0
Study 17397703 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagine-self perspective-taking
Number of subjects: 0
Study 17549950 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Stability (TS)
Number of subjects: 55
Study 17549950 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg Strength (LS)
Number of subjects: 55
Study 17549950 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Stability and Leg Strength (TL)
Number of subjects: 55
Study 17549950 — intervention group
Group type: COMPARATOR
Intervention: Control (CO)
Number of subjects: 55
Study 15286240 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral prophylaxis for HIV-exposed infants
Number of subjects: 0
Study 15286240 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring for early determination of HIV-1 infection status
Number of subjects: 0
Study 15286240 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis for Pneumocystis pneumonia
Number of subjects: 0
Study 15286240 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling to parents or caregivers
Number of subjects: 0
Study 10743871 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect
Number of subjects: 0
Study 8630203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone sodium phosphate (1 mg/kg up to 16 mg)
Number of subjects: 80
Study 8630203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 1600972 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 0
Study 1600972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3879176 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen suppositories (alpha‐methyl‐4‐(2‐thienylcarbonyl)‐phenyl acetic acid)
Number of subjects: 90
Study 31735613 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) filler injection
Number of subjects: 74
Study 31735613 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic Acid (PLA) filler injection
Number of subjects: 74
Study 30530189 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation group (ESG)
Number of subjects: 18
Study 30530189 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 18
Study 28831752 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 0.5 mg once daily for 8 weeks
Number of subjects: 48
Study 28831752 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 1.25 mg once daily for 8 weeks
Number of subjects: 48
Study 28831752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25281755 — intervention group
Group type: EXPERIMENTAL
Intervention: TCN‐032
Number of subjects: 0
Study 25281755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22973945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention including weekly nutrition and exercise education, exercise sessions, and nurse support (n = 51)
Number of subjects: 101
Study 22973945 — intervention group
Group type: COMPARATOR
Intervention: Control group received a 12-week healthy lifestyle booklet (n = 50)
Number of subjects: 101
Study 21301811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin 10 IU
Number of subjects: 24
Study 21301811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin 20 IU
Number of subjects: 24
Study 21301811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19645964 — intervention group
Group type: EXPERIMENTAL
Intervention: REMD (n = 17)
Number of subjects: 35
Study 19645964 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 18)
Number of subjects: 35
Study 17106665 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc prosthesis
Number of subjects: 25
Study 17106665 — intervention group
Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 25
Study 17106665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Disc prosthesis and ACDF)
Number of subjects: 25
Study 14731173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollow screw (HS) implants
Number of subjects: 89
Study 14731173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollow cylinder (HC) implants
Number of subjects: 89
Study 14731173 — intervention group
Group type: EXPERIMENTAL
Intervention: Angulated hollow cylinder (AHC) implants
Number of subjects: 89
Study 11718071 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin intervention group
Number of subjects: 488
Study 11718071 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 488
Study 9208074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 0.3 mg.kg‐1 with intravenous midazolam 2 mg
Number of subjects: 40
Study 9208074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ketamine and midazolam)
Number of subjects: 40
Study 8355505 — intervention group
Group type: COMPARATOR
Intervention: Very low-dose cytosine arabinoside (VLD-AC)
Number of subjects: 39
Study 8355505 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aclarubicin (LC-ACR)
Number of subjects: 39
Study 3325317 — intervention group
Group type: EXPERIMENTAL
Intervention: split‐virion influenza vaccine (MFV‐Ject, Institut Merieux)
Number of subjects: 19
Study 3325317 — intervention group
Group type: COMPARATOR
Intervention: sub‐unit vaccine (Fluvirin, Evans)
Number of subjects: 19
Study 31629915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 243
Study 31629915 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four cycles followed by nivolumab 3 mg/kg every 2 weeks
Number of subjects: 243
Study 31629915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 243
Study 31629915 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab
Number of subjects: 243
Study 29751360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative fluorescence angiography (IFA)
Number of subjects: 880
Study 29751360 — intervention group
Group type: COMPARATOR
Intervention: Standard care (surgery with no IFA)
Number of subjects: 880
Study 26862693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 61
Study 26862693 — intervention group
Group type: COMPARATOR
Intervention: K3 rotary system
Number of subjects: 61
Study 25139589 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (1800-2400 mg)
Number of subjects: 97
Study 25139589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 25139589 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 97
Study 22917575 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive valganciclovir therapy
Number of subjects: 70
Study 22917575 — intervention group
Group type: COMPARATOR
Intervention: Valacyclovir prophylaxis
Number of subjects: 70
Study 20815183 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (2 x 100 mg)
Number of subjects: 22
Study 20815183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20815183 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 22
Study 18279531 — intervention group
Group type: EXPERIMENTAL
Intervention: Current evidence‐based strategies for management and prevention of CDAD
Number of subjects: 0
Study 18279531 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 16192544 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block (ICB)
Number of subjects: 120
Study 16192544 — intervention group
Group type: COMPARATOR
Intervention: Humeral block (HB)
Number of subjects: 120
Study 11956450 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg finasteride
Number of subjects: 157
Study 11956450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 9503219 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% low‐molecular weight hydroxyethylstarch (HES) for 5 days
Number of subjects: 300
Study 9503219 — intervention group
Group type: COMPARATOR
Intervention: 20% human albumin (HA) for 5 days
Number of subjects: 300
Study 9503219 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% low‐molecular weight hydroxyethylstarch (HES) for 5 days (HES‐sepsis)
Number of subjects: 300
Study 9503219 — intervention group
Group type: COMPARATOR
Intervention: Volume replacement using albumin
Number of subjects: 300
Study 9503219 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume therapy with 10% HES for 5 days
Number of subjects: 300
Study 8564565 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 0
Study 8564565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ATRA + chemotherapy
Number of subjects: 0
Study 8564565 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 2796891 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure (COHb level of about 17%)
Number of subjects: 0
Study 2796891 — intervention group
Group type: COMPARATOR
Intervention: Room air (control group)
Number of subjects: 0
Study 81323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 87
Study 81323 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 87
Study 31322552 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (brachial plexus anesthesia on blocked side)
Number of subjects: 45
Study 31322552 — intervention group
Group type: COMPARATOR
Intervention: Group C (RIC conducted before regional anesthesia)
Number of subjects: 45
Study 31322552 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (brachial plexus anesthesia on non-blocked side)
Number of subjects: 45
Study 31322552 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 45
Study 28325638 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 3037
Study 28325638 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg daily
Number of subjects: 3037
Study 25691510 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy (PI)
Number of subjects: 0
Study 25691510 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (P-PCI)
Number of subjects: 0
Study 23447846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum fluid replacement
Number of subjects: 57
Study 23447846 — intervention group
Group type: COMPARATOR
Intervention: Restricted fluid replacement
Number of subjects: 57
Study 23447846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study 23447846 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake of 300 ml/h
Number of subjects: 57